In December 2012, the FDA approved Juxtapid (lomitapide) to reduce LDL-C, total cholesterol, apolipoprotein B, and non HDL-C in patients with HoFH.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia